Secukinumab in special psoriasis scenarios: our experience
DOI:
https://doi.org/10.47196/da.v31i2.2862Keywords:
secukinumab, psoriasis, pustular psoriasis, acrodermatitis continua of Hallopeau, erythrodermic psoriasisAbstract
Anti-interleukin-17 (anti-IL-17) biologics were approved by pivotal clinical trials for patients with moderate-severe psoriasis vulgaris and psoriatic arthritis. However, its indication in other less common varieties of psoriasis has been reported in various real-life studies. Four cases of patients with special varieties of psoriasis treated with secukinumab with excellent results are presented: three patients with pustular psoriasis, within which two forms were generalized and one was localized (Hallopeau's acrodermatitis continua) and one patient with erythrodermic psoriasis. In our experience, secukinumab proved to be effective and safe in these forms of psoriasis, as in series previously published in the literature.
References
I. Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clinic Rev Allerg Immunol. 2018;55:379-390.
II. Martin DA, Towne JE, Kricorian G, Klekotka P, et ál. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol 2013;133:17-26.
III. Rønholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017; 18:2297.
IV. Gordon KB, Foley P, Krueger JG, Pinter, A, et ál. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397:475-486.
V. Potestio L, Camela E, Cacciapuoti S, Fornaro L, et ál. Biologics for the management of erythrodermic psoriasis: an updated review. Clin Cosmet Investig Dermatol. 2023;16:2045-2059.
VI. Imafuku S, Honma M, Okubo Y, Komine M, et ál. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis. A 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43:1011-1017.
VII. Galluzzo M, D'Adamio S, Teoli M, Bianchi L, et ál. Biologic therapy for acrodermatitis continua of Hallopeau. Successful treatment with secukinumab and review of the literature. Dermatol Ther. 2019;32:e12899.
VIII. Menter A, Van Voorhees AS, Hsu S. Pustular psoriasis. A narrative review of recent developments in pathophysiology and therapeutic options. Dermatol Ther (Heidelb). 2021;11:1917-1929.
IX. Reymundo A, Vilarrasa E, Baniandrés O, Rodríguez-Fernández-Freire L, et ál. Effectiveness and safety profile of secukinumab for the treatment of patients with generalized pustular psoriasis in daily practice. J Eur Acad Dermatol Venereol. 2022;36:e849-e851.
X. Wilsmann-Theis D, Schnell LM, Ralser-Isselstein V, Bieber T, et ál. Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations. J Dermatol. 2018;45:850-854.
XI. Mugheddu C, Atzori L, Lappi A, Pau M, et ál. Successful secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis. J Eur Acad Dermatol Venereol. 2017;31:e420-e421.
XII. Polesie S, Lidholm G. Secukinumab in the treatment of generalized pustular psoriasis: a case report. Acta Derm Venereol. 2017;97:124-125.
XIII. Risum G. Psoriasis exacerbated by hypoparathyroidism with hypocalcaemia. Br J Dermatol. 1973;89:309-312.
XIV. Guerreiro de Moura CA, de Assis LH, Góes P, Rosa F, et ál. A case of acute generalized pustular psoriasis of von Zumbusch triggered by hypocalcemia. Case Rep Dermatol. 2015;7:345-351.
XV. Jo SJ, Park JY, Yoon HS, Youn JI. Case of acrodermatitis continua accompanied by psoriatic arthritis. J Dermatol. 2006;33:787-791.
XVI. Brill TJ, Elshorst-Schmidt T, Valesky EM, Kaufmann R, et ál. Successful treatment of acrodermatitis continua of Hallopeau with sequential combination of calcipotriol and tacrolimus ointments. Dermatology. 2005;211:351-355.
XVII. Galluzzo M, D'Adamio S, Teoli M, Bianchi L, et ál. Biologic therapy for acrodermatitis continua of Hallopeau. Successful treatment with secukinumab and review of the literature. Dermatol Ther. 2019;32:e12899.
XVIII. Blair HA. Spesolimab: first approval. Drugs. 2022;82:1681-1686.
XIX. Viguier M, Pagès C, Aubin F, Delaporte E, et ál. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. Br J Dermatol. 2012;167:417-423.
XX. Bhatnagar A, Singh GK, Deshpande SK, Mitra B, et ál. Use of secukinumab in erythrodermic psoriasis. A single center experience. Med J Armed Forces India. 2023;79 (Suppl 1):S6-S12.
XXI. Sociedad Argentina de Dermatología. Consenso nacional de psoriasis. Guía de tratamiento. Actualización 2024. Disponible en: https://sad.org.ar/wp-content/uploads/2024/08/CONSENSO-NACIONAL-PSORIASIS-2024.pdf. [Consultado enero 2025 ].
Downloads
Published
Issue
Section
License
Copyright (c) 2025 on behalf of the authors. Reproduction rights: Argentine Society of Dermatology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
El/los autor/es tranfieren todos los derechos de autor del manuscrito arriba mencionado a Dermatología Argentina en el caso de que el trabajo sea publicado. El/los autor/es declaran que el artículo es original, que no infringe ningún derecho de propiedad intelectual u otros derechos de terceros, que no se encuentra bajo consideración de otra revista y que no ha sido previamente publicado.
Le solicitamos haga click aquí para imprimir, firmar y enviar por correo postal la transferencia de los derechos de autor
